Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 10Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Skin Neoplasms 6Prostatic Neoplasms 5Neoplasm Metastasis 5Melanoma 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Merkel Cell 4Breast Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Mycosis Fungoides 3Carcinoma, Squamous Cell 3Carcinoma, Hepatocellular 3Carcinoma, Basal Cell 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Rectal Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Mesothelioma, Malignant 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

trametinib 8dabrafenib 7pembrolizumab 5Paclitaxel 5lenvatinib 4Radiotherapy, Intensity-Modulated 3Doxorubicin 3fosbretabulin 2cobimetinib 2cemiplimab 2atezolizumab 2Vemurafenib 2Sorafenib 2Nivolumab 2Bevacizumab 2zimberelimab 1tremelimumab 1selpercatinib 1sapanisertib 1sacituzumab govitecan 1pegfilgrastim 1fludarabine 1efatutazone 1durvalumab 1ceritinib 1cabozantinib 1aldesleukin 1abemaciclib 1Thyroidectomy 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Thyroid Carcinoma, Anaplastic × cemiplimab × Clear all
NCT07470489 2026-04-16

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
12 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT06902376 2025-11-05

NEO-COMBATXL

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
12 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡